![](https://courses.mededicus.com/sites/default/files/styles/course_image/public/course/2024-03/302.2D%20Banner_120x140.jpg?itok=nH4kolIm)
DED Magnified: A Real-World Case Library - Case 4
Activity Description and Purpose
In this fourth and final installment of DED Magnified: A Real-World Case Library Series, Darrell E. White, MD, describes his tailored approach to treating a patient with dry eye disease (DED). With recent additions to treatment options for DED, clinicians can now target the underlying causes of their individual patient’s DED more effectively by regularly assessing the patient’s response to treatment and making adjustments as needed.
Target Audience
This educational activity is intended for ophthalmologists and optometrists.
Learning Objectives
- Review causative factors of dry eye disease
- Design evidence-based treatment plans for persons with dry eye disease
Faculty
![]() | Darrell E. White, MD |
Disclosure Policy
MedEdicus adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been identified and mitigated by MedEdicus prior to the commencement of the activity.
Faculty
Darrell E. White, MD, is a consultant for AbbVie Inc, Aldeyra Therapeutics, Bausch & Lomb Incorporated, Bruder Healthcare, Johnson & Johnson Vision Care, Inc, Novartis Pharmaceuticals Corporation, Orasis Pharmaceuticals, Oyster Point Pharma, Inc, Santen Inc, Sun Pharmaceutical Industries, Inc, Tarsus Pharmaceuticals, Inc, Trukera, and Viatris Inc; is on the speakers bureau for AbbVie Inc, Bausch & Lomb Incorporated, Oyster Point Pharma, Inc, Sun Pharmaceutical Industries, Inc, and Viatris; and has stock options that have not been exercised in Oyster Point Pharma, Inc.
Peer Reviewer
This activity was peer reviewed. The peer reviewer has no relevant commercial relationships to disclose.
Planners, Managers, and Writers
MedEdicus planners, managers, and writers have no relevant commercial relationships to disclose.
Accreditation Statement
MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
MedEdicus LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
COPE approved for 0.75 CE credit for optometrists.
COPE Course ID: 92247-TD (Asynchronous)
COPE Course Category: Treatment/Management of Ocular Disease
Administrator:
This activity, COPE Activity Number 128804, is accredited by COPE for continuing education for optometrists.
Disclosure of Commercial Support
MedEdicus has received commercial support from Bausch & Lomb Incorporated for this activity in the form of an unrestricted educational grant.
The content of this ACCME-/COPE-accredited CME/CE activity was planned and prepared independently by MedEdicus without input from members of an ineligible company.
Off-Label Discussion
This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.
Sponsored by ![](https://courses.mededicus.com/sites/default/files/SUNY-logo.jpg)
Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at info@mededicus.com.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of State University of New York College of Optometry, MedEdicus LLC, or Bausch & Lomb Incorporated.
This CME/CE activity is copyrighted to MedEdicus LLC ©2024. All rights reserved. MedEdicus does not claim copyright to material included herein owned by third parties for which attribution or citation has been made. 302.2d
Available Credit
- 0.75 AMA PRA Category 1 Credit™
- 0.75 COPE
- 0.75 Participation